The Board of Directors of BOAN BIOTECH (06955) has been notified by its controlling shareholder, LUYE PHARMA Group, that, pursuant to the terms of a subscription agreement related to exchangeable preferred shares, an arrangement is planned. LUYE PHARMA's wholly-owned subsidiary, Shandong Luye Pharmaceutical Co., Ltd., intends to further transfer 38.5 million H shares on the market to the issuer, Luye Geneora Holding Limited, on January 22, 2026, as part of the proposed transfer.